Home Cart Sign in  
Chemical Structure| 302543-62-0 Chemical Structure| 302543-62-0

Structure of Rosiglitazone HCl
CAS No.: 302543-62-0

Chemical Structure| 302543-62-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Rosiglitazone HCl is a blood glucose-lowering drug, stimulating insulin secretion by binding to the PPAR receptors in fat cells.

Synonyms: BRL 49653 hydrochloride; Rosiglitazone hydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Rosiglitazone HCl

CAS No. :302543-62-0
Formula : C18H20ClN3O3S
M.W : 393.89
SMILES Code : O=C(N1)SC(CC2=CC=C(OCCN(C)C3=NC=CC=C3)C=C2)C1=O.[H]Cl
Synonyms :
BRL 49653 hydrochloride; Rosiglitazone hydrochloride
MDL No. :MFCD04112701

Safety of Rosiglitazone HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H317-H319
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00484419 Type 2 Diabetes ... More >> Hyperlipidemia Less << Phase 3 Completed - United States, California ... More >> La Mesa, California, United States Los Angeles, California, United States Los Gatos, California, United States San Antonio, California, United States United States, Florida Chiefland, Florida, United States United States, Indiana Gary, Indiana, United States United States, Maryland Baltimore, Maryland, United States United States, Michigan Dearborn, Michigan, United States W. Bloomfield, Michigan, United States United States, Nevada Las Vegas, Nevada, United States United States, New York Yonkers, New York, United States United States, North Carolina Lexington, North Carolina, United States Winston-Salem, North Carolina, United States United States, Ohio Munroe Falls, Ohio, United States Zaneville, Ohio, United States United States, Oregon Portland, Oregon, United States United States, Pennsylvania Jersey Shore, Pennsylvania, United States United States, South Carolina Clemson, South Carolina, United States United States, Tennessee Harriman, Tennessee, United States United States, Texas Dallas, Texas, United States Less <<
NCT00680745 Type 2 Diabetes Phase 3 Completed - -
NCT00484419 - Completed - -
NCT00386100 Diabetes Mellitus, Type 2 Phase 4 Completed - -
NCT00680745 - Completed - -
NCT00131664 Type 2 Diabetes Mellitus Phase 3 Completed - Canada, Ontario ... More >> Canadian Heart Research Centre Toronto, Ontario, Canada, m5b 2p9 Less <<
NCT00131664 - Completed - -
NCT00386100 - Completed - -
NCT01332071 Diabetes Mellitus, Type 2 Phase 1 Completed - Brazil ... More >> GSK Investigational Site Goiania, Goiás, Brazil Less <<
NCT00361868 Dyslipidemia ... More >>Glucose Metabolism Disorder Less << Phase 3 Terminated(The study was disco... More >>ntinued prematurely at the end of March 2007 due to slow enrolment.) Less << - -
NCT00499707 Diabetes Mellitus, Type 2 Phase 3 Completed - -
NCT00933309 Breast Cancer Phase 1 Completed - United States, Texas ... More >> UT MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00297063 Diabetes Mellitus, Type 2 Phase 3 Completed - Japan ... More >> GSK Investigational Site Hokkaido, Japan, 051-0005 GSK Investigational Site Ibaraki, Japan, 311-0113 GSK Investigational Site Kanagawa, Japan, 224-0024 GSK Investigational Site Tokyo, Japan, 125-0054 GSK Investigational Site Tokyo, Japan, 130-0004 Less <<
NCT00015691 HIV Infections ... More >> Lipodystrophy Hyperinsulinemia Less << Not Applicable Completed - -
NCT01332071 - Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.54mL

0.51mL

0.25mL

12.69mL

2.54mL

1.27mL

25.39mL

5.08mL

2.54mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories